Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.75 |
| ▸ | MEN1 | O00255 | 3/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.54 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30892438 | 0.86 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL3101531 | 0.84 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL11880773 | 0.83 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL695019 | 0.83 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL13157463 | 0.81 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL693052 | 0.80 | ALDH1A1 (0.70) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL29432526 | 0.79 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2KMT2ALMNAL3MBTL1 | |
| SCHEMBL11964590 | 0.78 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL19720320 | 0.77 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL13108359 | 0.76 | L3MBTL1 (0.51) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2749554-B1 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | SMA THERAPEUTICS INC (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-2749554-B1 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | SMA THERAPEUTICS INC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20160031841-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031841-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9187425-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187425-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2749554-A2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | Axikin Pharmaceuticals, Inc. (US) | 2014-07-02 | — | — | EP | disclosed |
| EP-2749554-A2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | Axikin Pharmaceuticals, Inc. (US) | 2014-07-02 | — | — | EP | disclosed |
| US-20140066446-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066446-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130065889-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8318747-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318747-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318747-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2421830-A2 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | Axikin Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010123959-A2 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123959-A2 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273785-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100273785-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100273785-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031841-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | ALDH1A1 1349/4885SMN1; SMN2 603/4885KMT2A 2893/4885 |
| US-20100273785-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | ALDH1A1 2329/4885SMN1; SMN2 819/4885KMT2A 2754/4885 |
| US-20140066446-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | ALDH1A1 1349/4885SMN1; SMN2 603/4885KMT2A 2893/4885 |
| US-20130065889-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | ALDH1A1 1349/4885SMN1; SMN2 603/4885KMT2A 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.